HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that CEO Robert Eno and CFO Timothy Cruickshank will attend the MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference in September 2025. During these conferences, Mr. Eno and Mr. Cruickshank will meet with strategic and industry partners and update investors on HeartBeam’s progress towards commercialization.

The MDB Investor Summit 2025 is being held at the Old Parkland, Nurse’s Quarters Building in Dallas, TX on September 4, 2025. During the event, HeartBeam will meet with new and existing investors in a CEO Small Group Session, Big Idea Updates and Q&A, and conduct live demos of its FDA-cleared HeartBeam System. The cleared HeartBeam System is a cable-free, credit card-sized device capable of collecting ECG signals in 3D (from three non-coplanar directions) for arrhythmia assessment.

HRX Live 2025 being held in Atlanta, GA, from September 4-6, 2025. Dr. Joshua Lampert, Cardiac Electrophysiologist and Medical Director of Machine Learning at Mount Sinai Heart in the Mount Sinai Hospital, will present new data comparing the performance of HeartBeam’s AI algorithm on standard 12-lead ECGs and proprietary non-coplanar ECG signals recorded with the HeartBeam System for detecting atrial flutter and fibrillation. The presentation will take place during the AbstractX Happy Hour on September 4 beginning at 5:30 pm Eastern time.

H.C. Wainwright 27th Annual Global Investment Conference is being held at the Lotte New York Palace Hotel in New York, NY from September 8-10, 2025. During the conference, HeartBeam will participate in one-on-one meetings with institutional investors and host a live, in-person presentation on September 9 starting at 5:00 p.m. Eastern time.

For more information on the MDB Investor Summit 2025, HRX Live 2025, H.C. Wainwright 27th Annual Global Investment Conference, or to schedule a meeting with HeartBeam management, please contact your conference representative or you may also email your request to BEAT@mzgroup.us or call Chris Tyson at (949) 491-8235.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Cleared Indications for Use

The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828005484/en/